Clinical trial collaboration and supply agreement between Boehringer and BioNTech to conduct a Phase Ib/II clinical trial to explore ...
The vascular endothelial growth factor (VEGF) pathway is well established as one of the key regulators of this process. The VEGF/VEGF-receptor axis is composed of multiple ligands and receptors with ...
MELBOURNE, Australia and PRINCETON, N.J., July 09, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel ...
BUFFALO, NY- February 9, 2023 – A new research paper was published in Oncotarget's Volume 14 on February 2, 2023, entitled, “Everolimus downregulates STAT3/HIF-1α/VEGF pathway to inhibit angiogenesis ...
Researchers with The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) have identified a new molecular drug ...
The FDA has granted Orphan Drug Designation to tovecimig (CTX-009) for the treatment of patients with biliary tract cancer ...
Boehringer Ingelheim to evaluate combination of DLL3-targeting T-cell engager plus PD-L1/VEGF-A bispecific antibody in small cell lung cancer: Ingelheim, Germany Saturday, April 1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results